|
ý
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For the quarterly period ended September 30, 2015
|
¨
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For transition period from to
|
|
|
Delaware
|
94-3023969
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
Large accelerated filer
ý
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
¨
|
(Do not check if a smaller reporting company)
|
|
Page
|
|
GLOSSARY OF TERMS AND ABBREVIATIONS (as used in this document)
|
||
|
||
PART I - FINANCIAL INFORMATION
|
||
|
|
|
ITEM 1.
|
FINANCIAL STATEMENTS
|
|
|
|
|
|
Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2015 and 2014
|
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2015 and 2014
|
|
|
|
|
|
Condensed Consolidated Balance Sheets at September 30, 2015, and December 31, 2014
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014
|
|
|
|
|
|
Notes to the Condensed Consolidated Financial Statements
|
|
|
|
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
|
|
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
|
|
|
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
|
|
||
PART II - OTHER INFORMATION
|
||
|
|
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
|
|
|
|
ITEM 1A.
|
RISK FACTORS
|
|
|
|
|
ITEM 6.
|
EXHIBITS
|
|
|
|
|
SIGNATURES
|
Abbreviation/term
|
|
Definition
|
|
|
|
'216B Patent
|
|
European Patent No. 0 451 216B
|
'761 Patent
|
|
U.S. Patent No. 5,693,761
|
AbbVie
|
|
AbbVie Biotherapeutics, Inc.
|
Accel 300
|
|
Accel 300, LLC, a wholly-owned subsidiary of kaléo, Inc.
|
AcelRx
|
|
AcelRx Pharmaceuticals, Inc.
|
AcelRx Royalty Agreement
|
|
Royalty Interest Assignment Agreement, dated September 18, 2015, between PDL and AcelRx
|
APIC
|
|
Additional paid-in-capital
|
ARIAD
|
|
ARIAD Pharmaceuticals, Inc.
|
ARIAD Royalty Agreement
|
|
Royalty Interest Assignment Agreement, dated July 28, 2015, between PDL and ARIAD
|
ARIAD Royalty Rights
|
|
The right to receive specified royalties on ARIAD’s Net Revenues (as defined in the ARIAD Royalty Agreement) generated by the sale, distribution or other use of ARIAD’s product Iclusig
®
(ponatinib)
|
ASC
|
|
Accounting Standards Codification
|
ASU
|
|
Accounting Standards Update
|
Avinger
|
|
Avinger, Inc.
|
Avinger Credit and Royalty Agreement
|
|
Credit Agreement, dated April 18, 2013, between PDL and Avinger
|
AxoGen
|
|
AxoGen, Inc.
|
AxoGen Royalty Agreement
|
|
Revenue Interests Purchase Agreement, dated as of October 5, 2012, between PDL and AxoGen
|
Biogen
|
|
Biogen, Inc.
|
CareView
|
|
CareView Communications, Inc.
|
Chugai
|
|
Chugai Pharmaceutical Co., Ltd.
|
Depo DR Sub
|
|
Depo DR Sub, LLC, a wholly-owned subsidiary of Depomed
|
Depomed
|
|
Depomed, Inc.
|
Depomed Royalty Agreement
|
|
Royalty Purchase and Sale Agreement, dated as of October 18, 2013, among Depomed, Depo DR Sub and PDL
|
Direct Flow Medical
|
|
Direct Flow Medical, Inc.
|
Durata
|
|
Durata Therapeutics Holding C.V., Durata Therapeutics International B.V. and Durata Therapeutics, Inc. (parent company)
|
EBITDA
|
|
Earnings before interest, taxes, depreciation and amortization
|
Elan
|
|
Elan Corporation, PLC
|
EPO
|
|
European Patent Office
|
ex-U.S.-based Manufacturing and Sales
|
|
Products that are both manufactured and sold outside of the United States
|
ex-U.S.-based Sales
|
|
Products that are manufactured in the United States and sold outside of the United States
|
Facet
|
|
Facet Biotech Corporation. In April 2010, Abbott Laboratories acquired Facet and later renamed the company Abbott Biotherapeutics Corp., and in January 2013, Abbott Biotherapeutics Corp. was renamed AbbVie Biotherapeutics, Inc. and spun off from Abbott Laboratories as a subsidiary of AbbVie Inc.
|
FASB
|
|
Financial Accounting Standards Board
|
FDA
|
|
U.S. Food and Drug Administration
|
February 2015 Notes
|
|
2.875% Convertible Senior Notes due February 15, 2015, fully retired at September 30, 2013
|
February 2018 Notes
|
|
4.0% Convertible Senior Notes due February 1, 2018
|
GAAP
|
|
U.S. Generally Accepted Accounting Principles
|
Genentech
|
|
Genentech, Inc.
|
Genentech Products
|
|
Avastin
®
, Herceptin
®
, Lucentis
®
, Xolair
®
, Perjeta
®
and Kadcyla
®
|
Genzyme
|
|
Genzyme Corporation (a Sanofi company)
|
Hyperion
|
|
Hyperion Catalysis International, Inc.
|
IRS
|
|
Internal Revenue Service
|
kaléo
|
|
kaléo, Inc. (formerly known as Intelliject, Inc.)
|
kaléo Revenue Interests
|
|
100% of the royalties from kaléo’s first approved product, Auvi-Q™ (epinephrine auto-injection, USP) (known as Allerject in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection), collectively
|
KMPG
|
|
KPMG, LLP
|
LENSAR
|
|
LENSAR, Inc.
|
Lilly
|
|
Eli Lilly and Company
|
March 2015 Term Loan
|
|
Term Loan borrowed under the Credit Agreement, dated as of March 30, 2015, among PDL, the Royal Bank of Canada and lenders thereto
|
May 2015 Notes
|
|
3.75% Senior Convertible Notes due May 2015
|
Merck
|
|
Merck & Co., Inc.
|
Michigan Royalty Agreement
|
|
Royalty Purchase and Sale Agreement, dated as of November 6, 2014, between The Regents of the University of Michigan and PDL
|
Novartis
|
|
Novartis AG
|
OCI
|
|
Other Comprehensive Income (Loss)
|
October 2013 Term Loan
|
|
Term Loan borrowed under the Credit Agreement, dated October 28, 2013, among PDL, the Royal Bank of Canada and lenders thereto, as amended
|
Paradigm Spine
|
|
Paradigm Spine, LLC
|
Paradigm Spine Credit Agreement
|
|
Paradigm Spine Credit Agreement, dated February 14, 2014, between Paradigm Spine and the Company
|
PDL, we, us, our, the Company
|
|
PDL BioPharma, Inc.
|
Queen et al. patents
|
|
PDL's patents in the United States and elsewhere covering the humanization of antibodies
|
Roche
|
|
F. Hoffman LaRoche, Ltd.
|
Salix
|
|
Salix Pharmaceuticals, Inc.
|
Santarus
|
|
Santarus, Inc.
|
SDK
|
|
Showa Denka K.K.
|
SEC
|
|
Securities and Exchange Commission
|
Series 2012 Notes
|
|
2.875% Series 2012 Convertible Senior Notes, fully retired on February 15, 2015
|
Settlement Agreement
|
|
Settlement Agreement between and among PDL, Genentech and Roche, dated January 31, 2014
|
SPCs
|
|
Supplementary Protection Certificates
|
SPC Products
|
|
Avastin, Herceptin, Lucentis, Xolair and Tysabri
|
Spin-Off
|
|
The spin-off by PDL of Facet
|
Takeda
|
|
Takeda Pharmaceuticals America, Inc.
|
U-M
|
|
University of Michigan
|
Valeant Pharmaceuticals
|
|
Valeant Pharmaceuticals International, Inc.
|
VB
|
|
Viscogliosi Brothers, LLC
|
VB Royalty Agreement
|
|
Royalty Purchase and Sale Agreement, dated as of June 26, 2014, between Viscogliosi Brothers, LLC and PDL
|
VWAP
|
|
Volume-weighted average share price
|
Wellstat Diagnostics
|
|
Wellstat Diagnostics, LLC
|
Wellstat Diagnostics Borrower Notice
|
|
A notice of default to Wellstat Diagnostics, due to, inter alia, its ongoing failure to pay its debts as they became due and Wellstat Diagnostics' failure to comply with certain covenants included in the first amendment to amended and restated credit agreement by the deadlines to which the parties had agreed
|
Wellstat Diagnostics Guarantor Notice
|
|
A notice to each of the guarantors of Wellstat Diagnostics' obligations to the Company under the credit agreement
|
Wellstat Diagnostics Guarantors
|
|
Some or all of: Samuel J. Wohlstadter; Nadine H. Wohlstadter; Duck Farm, Inc.; Hebron Valley Farms, Inc.; HVF, Inc.; Hyperion Catalysis EU Limited; Hyperion Catalysis International, Inc.; NHW, LLC; Wellstat AVT Investment, LLC; Wellstat Biocatalysis, LLC; Wellstat Biologics Corporation; Wellstat Diagnostics, LLC; Wellstat Immunotherapeutics, LLC; Wellstat Management Company, LLC; Wellstate Opthalmics Corporation; Wellstat Therapeutics Corporation; Wellstat Therapeutics EU Limited; Wellstat Vaccines, LLC; and SJW Properties, Inc.
|
Wellstat Diagnostics Note Receivable and Credit Agreement
|
|
Senior Secured Note receivable among the Company and the holders of the equity interests in Wellstat Diagnostics, as amended, and Credit Agreement between Wellstat Diagnostics and the Company, dated November 2, 2012, as amended
|
Wellstat Diagnostics Petition
|
|
An Ex Parte Petition for Appointment of Receiver with the Circuit Court of Montgomery County, Maryland
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Revenues
|
|
|
|
|
|
|
|
|
||||||||
Royalties from Queen et al. patents
|
|
$
|
119,222
|
|
|
$
|
123,916
|
|
|
$
|
363,916
|
|
|
$
|
355,008
|
|
Royalty rights - change in fair value
|
|
(4,280
|
)
|
|
27,602
|
|
|
19,298
|
|
|
73,807
|
|
||||
Interest revenue
|
|
9,096
|
|
|
13,076
|
|
|
28,596
|
|
|
34,760
|
|
||||
License and other
|
|
580
|
|
|
—
|
|
|
580
|
|
|
575
|
|
||||
Total revenues
|
|
124,618
|
|
|
164,594
|
|
|
412,390
|
|
|
464,150
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
General and administrative
|
|
8,450
|
|
|
5,686
|
|
|
23,545
|
|
|
17,188
|
|
||||
Operating income
|
|
116,168
|
|
|
158,908
|
|
|
388,845
|
|
|
446,962
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Non-operating expense, net
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest and other income, net
|
|
87
|
|
|
75
|
|
|
294
|
|
|
207
|
|
||||
Interest expense
|
|
(5,901
|
)
|
|
(9,387
|
)
|
|
(21,710
|
)
|
|
(29,770
|
)
|
||||
Loss on extinguishment of debt
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6,143
|
)
|
||||
Total non-operating expense, net
|
|
(5,814
|
)
|
|
(9,312
|
)
|
|
(21,416
|
)
|
|
(35,706
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Income before income taxes
|
|
110,354
|
|
|
149,596
|
|
|
367,429
|
|
|
411,256
|
|
||||
Income tax expense
|
|
40,895
|
|
|
47,361
|
|
|
135,208
|
|
|
144,083
|
|
||||
Net income
|
|
$
|
69,459
|
|
|
$
|
102,235
|
|
|
$
|
232,221
|
|
|
$
|
267,173
|
|
|
|
|
|
|
|
|
|
|
||||||||
Net income per share
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
|
$
|
0.42
|
|
|
$
|
0.64
|
|
|
$
|
1.42
|
|
|
$
|
1.70
|
|
Diluted
|
|
$
|
0.42
|
|
|
$
|
0.61
|
|
|
$
|
1.42
|
|
|
$
|
1.62
|
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
|
163,560
|
|
|
160,268
|
|
|
163,314
|
|
|
157,274
|
|
||||
Diluted
|
|
163,742
|
|
|
166,894
|
|
|
163,899
|
|
|
165,141
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Cash dividends declared per common share
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.60
|
|
|
$
|
0.60
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Net income
|
|
$
|
69,459
|
|
|
$
|
102,235
|
|
|
$
|
232,221
|
|
|
$
|
267,173
|
|
|
|
|
|
|
|
|
|
|
||||||||
Other comprehensive income (loss), net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in unrealized gains on investments in available-for-sale securities:
|
|
|
|
|
|
|
|
|
||||||||
Change in fair value of investments in available-for-sale securities, net of tax
|
|
634
|
|
|
(258
|
)
|
|
445
|
|
|
(1,554
|
)
|
||||
Adjustment for net (gains) losses realized and included in net income, net of tax
|
|
(406
|
)
|
|
—
|
|
|
(406
|
)
|
|
—
|
|
||||
Total change in unrealized gains on investments in available-for-sale securities, net of tax
(a)
|
|
228
|
|
|
(258
|
)
|
|
39
|
|
|
(1,554
|
)
|
||||
Change in unrealized gains (losses) on cash flow hedges:
|
|
|
|
|
|
|
|
|
||||||||
Change in fair value of cash flow hedges, net of tax
|
|
(57
|
)
|
|
1,974
|
|
|
4,306
|
|
|
2,305
|
|
||||
Adjustment to royalties from Queen et al. patents for net (gains) losses realized and included in net income, net of tax
|
|
(1,495
|
)
|
|
989
|
|
|
(3,903
|
)
|
|
3,744
|
|
||||
Total change in unrealized losses on cash flow hedges, net of tax
(b)
|
|
(1,552
|
)
|
|
2,963
|
|
|
403
|
|
|
6,049
|
|
||||
Total other comprehensive income (loss), net of tax
|
|
(1,324
|
)
|
|
2,705
|
|
|
442
|
|
|
4,495
|
|
||||
Comprehensive income
|
|
$
|
68,135
|
|
|
$
|
104,940
|
|
|
$
|
232,663
|
|
|
$
|
271,668
|
|
|
September 30,
|
|
December 31,
|
||||
|
2015
|
|
2014
|
||||
|
(unaudited)
|
|
(Note 1)
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
227,855
|
|
|
$
|
291,377
|
|
Short-term investments
|
1,827
|
|
|
2,310
|
|
||
Receivables from licensees and other
|
594
|
|
|
300
|
|
||
Deferred tax assets
|
—
|
|
|
375
|
|
||
Notes receivable
|
67,246
|
|
|
57,597
|
|
||
Prepaid and other current assets
|
9,166
|
|
|
3,938
|
|
||
Total current assets
|
306,688
|
|
|
355,897
|
|
||
|
|
|
|
||||
Property and equipment, net
|
42
|
|
|
62
|
|
||
Royalty rights - at fair value
|
384,572
|
|
|
259,244
|
|
||
Notes and other receivables, long-term
|
286,160
|
|
|
305,615
|
|
||
Long-term deferred tax assets
|
36,499
|
|
|
33,799
|
|
||
Other assets
|
6,640
|
|
|
7,733
|
|
||
Total assets
|
$
|
1,020,601
|
|
|
$
|
962,350
|
|
|
|
|
|
||||
Liabilities and Stockholders' Equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
421
|
|
|
$
|
318
|
|
Accrued liabilities
|
32,711
|
|
|
8,876
|
|
||
Accrued income taxes
|
—
|
|
|
3,293
|
|
||
Deferred tax liabilities
|
11,615
|
|
|
—
|
|
||
Term loan payable
|
49,842
|
|
|
—
|
|
||
Convertible notes payable
|
—
|
|
|
175,496
|
|
||
Total current liabilities
|
94,589
|
|
|
187,983
|
|
||
|
|
|
|
||||
Convertible notes payable
|
281,581
|
|
|
276,228
|
|
||
Other long-term liabilities
|
48,474
|
|
|
37,702
|
|
||
Total liabilities
|
424,644
|
|
|
501,913
|
|
||
|
|
|
|
||||
Commitments and contingencies (Note 8)
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders' equity:
|
|
|
|
|
|
||
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding
|
—
|
|
|
—
|
|
||
Common stock, par value $0.01 per share, 350,000 shares authorized; 163,573 and 162,186 shares issued and outstanding at September 30, 2015, and December 31, 2014, respectively
|
1,636
|
|
|
1,622
|
|
||
Additional paid-in capital
|
(118,540
|
)
|
|
(119,874
|
)
|
||
Accumulated other comprehensive income
|
3,391
|
|
|
2,949
|
|
||
Retained earnings
|
709,470
|
|
|
575,740
|
|
||
Total stockholders' equity
|
595,957
|
|
|
460,437
|
|
||
Total liabilities and stockholders' equity
|
$
|
1,020,601
|
|
|
$
|
962,350
|
|
|
Nine Months Ended September 30,
|
||||||
|
2015
|
|
2014
|
||||
Cash flows from operating activities
|
|
|
|
||||
Net income
|
$
|
232,221
|
|
|
$
|
267,173
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Amortization of convertible notes and term loan offering costs
|
9,744
|
|
|
13,473
|
|
||
Change in fair value of royalty rights - at fair value
|
(19,298
|
)
|
|
(72,992
|
)
|
||
Loss on extinguishment of convertible notes
|
—
|
|
|
6,143
|
|
||
Other amortization, depreciation and accretion of embedded derivative
|
29
|
|
|
(144
|
)
|
||
Gain on sale of available-for-sale securities
|
(580
|
)
|
|
—
|
|
||
Hedge ineffectiveness on foreign exchange contracts
|
—
|
|
|
(5
|
)
|
||
Stock-based compensation expense
|
1,348
|
|
|
1,026
|
|
||
Deferred income taxes
|
9,143
|
|
|
(6,493
|
)
|
||
Changes in assets and liabilities:
|
|
|
|
|
|
||
Receivables from licensees and other
|
(294
|
)
|
|
50
|
|
||
Prepaid and other current assets
|
(4,434
|
)
|
|
1,959
|
|
||
Accrued interest on notes receivable
|
(3,076
|
)
|
|
(8,367
|
)
|
||
Other assets
|
35
|
|
|
(29
|
)
|
||
Accounts payable
|
103
|
|
|
792
|
|
||
Accrued liabilities
|
(861
|
)
|
|
3,325
|
|
||
Accrued income taxes
|
(3,293
|
)
|
|
6,494
|
|
||
Other long-term liabilities
|
10,599
|
|
|
10,834
|
|
||
Net cash provided by operating activities
|
231,386
|
|
|
223,239
|
|
||
Cash flows from investing activities
|
|
|
|
|
|
||
Proceeds from sales of available-for-sale securities
|
1,124
|
|
|
—
|
|
||
Purchase of royalty rights - at fair value
|
(115,000
|
)
|
|
(15,500
|
)
|
||
Proceeds from royalty rights - at fair value
|
8,970
|
|
|
81,717
|
|
||
Purchase of notes receivable
|
(8,976
|
)
|
|
(215,000
|
)
|
||
Repayment of notes receivable
|
20,600
|
|
|
—
|
|
||
Purchase of property and equipment
|
(9
|
)
|
|
(49
|
)
|
||
Net cash used in investing activities
|
(93,291
|
)
|
|
(148,832
|
)
|
||
Cash flows from financing activities
|
|
|
|
|
|
||
Proceeds from term loan
|
100,000
|
|
|
—
|
|
||
Repurchase of convertible notes
|
(177,387
|
)
|
|
(29,906
|
)
|
||
Payment of debt issuance costs
|
(607
|
)
|
|
(9,287
|
)
|
||
Proceeds from the issuance of convertible notes
|
—
|
|
|
300,000
|
|
||
Purchase of call options
|
—
|
|
|
(30,951
|
)
|
||
Proceeds from the issuance of warrants
|
—
|
|
|
11,427
|
|
||
Repayment of term loan
|
(50,000
|
)
|
|
(56,250
|
)
|
||
Cash dividends paid
|
(73,623
|
)
|
|
(72,135
|
)
|
||
Net cash provided by/(used in) financing activities
|
(201,617
|
)
|
|
112,898
|
|
||
Net increase/(decrease) in cash and cash equivalents
|
(63,522
|
)
|
|
187,305
|
|
||
Cash and cash equivalents at beginning of the period
|
291,377
|
|
|
94,302
|
|
||
Cash and cash equivalents at end of period
|
$
|
227,855
|
|
|
$
|
281,607
|
|
|
|
|
|
||||
|
|
|
|
||||
Supplemental cash flow information
|
|
|
|
|
|
||
Cash paid for income taxes
|
$
|
125,000
|
|
|
$
|
134,000
|
|
Cash paid for interest
|
$
|
16,045
|
|
|
$
|
15,217
|
|
Stock issued to settle debt
|
$
|
9,794
|
|
|
$
|
157,591
|
|
Warrant received for issuance of notes receivable
|
$
|
(1,258
|
)
|
|
$
|
—
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||
Licensee
|
|
Product Name
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
Genentech
|
|
Avastin
|
|
32
|
%
|
|
24
|
%
|
|
28
|
%
|
|
25
|
%
|
|
|
Herceptin
|
|
32
|
%
|
|
24
|
%
|
|
28
|
%
|
|
25
|
%
|
|
|
Xolair
|
|
10
|
%
|
|
6
|
%
|
|
8
|
%
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
||||
Biogen
|
|
Tysabri
®
|
|
11
|
%
|
|
10
|
%
|
|
10
|
%
|
|
9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depomed
|
|
Glumetza
®
|
|
(10
|
)%
|
|
14
|
%
|
|
—
|
%
|
|
13
|
%
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
Net Income per Basic and Diluted Share:
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
(in thousands except per share amounts)
|
|
|
|
|
|
|
|
|
||||||||
Numerator
|
|
|
|
|
|
|
|
|
||||||||
Net income used to compute net income per basic and diluted share
|
|
$
|
69,459
|
|
|
$
|
102,235
|
|
|
$
|
232,221
|
|
|
$
|
267,173
|
|
|
|
|
|
|
|
|
|
|
||||||||
Denominator
|
|
|
|
|
|
|
|
|
|
|
||||||
Weighted average shares used to compute net income per basic share
|
|
163,560
|
|
|
160,268
|
|
|
163,314
|
|
|
157,274
|
|
||||
Restricted stock outstanding
|
|
167
|
|
|
96
|
|
|
131
|
|
|
113
|
|
||||
Effect of dilutive stock options
|
|
15
|
|
|
22
|
|
|
18
|
|
|
22
|
|
||||
Assumed conversion of Series 2012 Notes
|
|
—
|
|
|
2,247
|
|
|
33
|
|
|
3,301
|
|
||||
Assumed conversion of warrants
|
|
—
|
|
|
—
|
|
|
403
|
|
|
—
|
|
||||
Assumed conversion of May 2015 Notes
|
|
—
|
|
|
4,261
|
|
|
—
|
|
|
4,431
|
|
||||
Weighted average shares used to compute net income per diluted share
|
|
163,742
|
|
|
166,894
|
|
|
163,899
|
|
|
165,141
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Net income per share - basic
|
|
$
|
0.42
|
|
|
$
|
0.64
|
|
|
$
|
1.42
|
|
|
$
|
1.70
|
|
Net income per share - diluted
|
|
$
|
0.42
|
|
|
$
|
0.61
|
|
|
$
|
1.42
|
|
|
$
|
1.62
|
|
|
|
September 30, 2015
|
|
December 31, 2014
|
||||||||||||||||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||||||||||
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Financial assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Money market funds
|
|
$
|
139,850
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
139,850
|
|
|
$
|
221,792
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
221,792
|
|
Corporate securities
|
|
—
|
|
|
1,827
|
|
|
—
|
|
|
1,827
|
|
|
—
|
|
|
2,310
|
|
|
—
|
|
|
2,310
|
|
||||||||
Foreign currency hedge contracts
|
|
—
|
|
|
4,597
|
|
|
—
|
|
|
4,597
|
|
|
—
|
|
|
4,069
|
|
|
—
|
|
|
4,069
|
|
||||||||
Warrants
|
|
—
|
|
|
1,258
|
|
|
—
|
|
|
1,258
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Royalty rights - at fair value
|
|
—
|
|
|
—
|
|
|
384,572
|
|
|
384,572
|
|
|
—
|
|
|
—
|
|
|
259,244
|
|
|
259,244
|
|
||||||||
Total
|
|
$
|
139,850
|
|
|
$
|
7,682
|
|
|
$
|
384,572
|
|
|
$
|
532,104
|
|
|
$
|
221,792
|
|
|
$
|
6,379
|
|
|
$
|
259,244
|
|
|
$
|
487,415
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||
|
|
|
|
|
|
|
||||
(in thousands)
|
|
|
Royalty Rights - At Fair Value
|
|||||||
Beginning Balance at December 31, 2014
|
|
|
$
|
259,244
|
|
|||||
|
|
|
|
|
|
|
||||
|
Total net change in fair value for the period
|
|
|
|
||||||
|
|
Change in fair value of royalty rights - at fair value
|
$
|
19,298
|
|
|
||||
|
|
Proceeds from royalty rights - at fair value
|
$
|
(8,970
|
)
|
|
||||
|
|
|
Total net change in fair value for the period
|
|
|
10,328
|
|
|||
|
Purchases, issues, sales, and settlements
|
|
|
|
||||||
|
|
Purchases
|
|
|
115,000
|
|
||||
|
|
|
|
|
|
|
||||
Ending Balance at September 30, 2015
|
|
|
$
|
384,572
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
(in thousands)
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Total change in fair value for the period included in earnings for assets held at the end of the reporting period
|
|
$
|
(4,280
|
)
|
|
$
|
26,787
|
|
|
$
|
19,298
|
|
|
$
|
72,992
|
|
|
|
September 30, 2015
|
|
December 31, 2014
|
||||||||||||||||||||
|
|
Carrying Value
|
|
Fair Value
Level 2
|
|
Fair Value
Level 3
|
|
Carrying Value
|
|
Fair Value
Level 2
|
|
Fair Value
Level 3
|
||||||||||||
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Wellstat Diagnostics note receivable
|
|
$
|
50,191
|
|
|
$
|
—
|
|
|
$
|
50,191
|
|
|
$
|
50,191
|
|
|
$
|
—
|
|
|
$
|
50,191
|
|
Hyperion note receivable
|
|
1,200
|
|
|
—
|
|
|
1,200
|
|
|
1,200
|
|
|
—
|
|
|
1,200
|
|
||||||
Avinger note receivable
|
|
—
|
|
|
—
|
|
|
—
|
|
|
20,611
|
|
|
—
|
|
|
20,760
|
|
||||||
LENSAR note receivable
|
|
50,266
|
|
|
—
|
|
|
50,266
|
|
|
39,668
|
|
|
—
|
|
|
40,451
|
|
||||||
Direct Flow Medical note receivable
|
|
51,772
|
|
|
—
|
|
|
52,052
|
|
|
50,397
|
|
|
—
|
|
|
49,940
|
|
||||||
Paradigm Spine note receivable
|
|
49,909
|
|
|
—
|
|
|
51,071
|
|
|
49,571
|
|
|
—
|
|
|
50,125
|
|
||||||
kaléo note receivable
|
|
151,496
|
|
|
—
|
|
|
151,476
|
|
|
151,574
|
|
|
—
|
|
|
151,073
|
|
||||||
Total
1
|
|
$
|
354,834
|
|
|
$
|
—
|
|
|
$
|
356,256
|
|
|
$
|
363,212
|
|
|
$
|
—
|
|
|
$
|
363,740
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Series 2012 Notes
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,261
|
|
|
$
|
33,506
|
|
|
$
|
—
|
|
May 2015 Notes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
153,235
|
|
|
205,534
|
|
|
—
|
|
||||||
February 2018 Notes
|
|
281,581
|
|
|
262,313
|
|
|
—
|
|
|
276,228
|
|
|
289,665
|
|
|
—
|
|
||||||
March 2015 Term Loan
|
|
49,842
|
|
|
50,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Total
|
|
$
|
331,423
|
|
|
$
|
312,313
|
|
|
$
|
—
|
|
|
$
|
451,724
|
|
|
$
|
528,705
|
|
|
$
|
—
|
|
Summary of Cash and Available-For-Sale Securities
|
|
Adjusted Cost
|
|
Unrealized Gains
|
|
Unrealized Losses
|
|
Estimated Fair Value
|
|
Cash and Cash Equivalents
|
|
Short-Term Investments
|
||||||||||||
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
September 30, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash
|
|
$
|
88,005
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
88,005
|
|
|
$
|
88,005
|
|
|
$
|
—
|
|
Money market funds
|
|
139,850
|
|
|
—
|
|
|
—
|
|
|
139,850
|
|
|
139,850
|
|
|
—
|
|
||||||
Corporate securities
|
|
1,206
|
|
|
621
|
|
|
—
|
|
|
1,827
|
|
|
—
|
|
|
1,827
|
|
||||||
Total
|
|
$
|
229,061
|
|
|
$
|
621
|
|
|
$
|
—
|
|
|
$
|
229,682
|
|
|
$
|
227,855
|
|
|
$
|
1,827
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
December 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash
|
|
$
|
69,585
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
69,585
|
|
|
$
|
69,585
|
|
|
$
|
—
|
|
Money market funds
|
|
221,792
|
|
|
—
|
|
|
—
|
|
|
221,792
|
|
|
221,792
|
|
|
—
|
|
||||||
Corporate securities
|
|
1,750
|
|
|
560
|
|
|
—
|
|
|
2,310
|
|
|
—
|
|
|
2,310
|
|
||||||
Total
|
|
$
|
293,127
|
|
|
$
|
560
|
|
|
$
|
—
|
|
|
$
|
293,687
|
|
|
$
|
291,377
|
|
|
$
|
2,310
|
|
Euro Forward Contracts
|
|
September 30, 2015
|
|
December 31, 2014
|
||||||||||||||||
|
|
|
|
|
|
(In thousands)
|
|
(In thousands)
|
||||||||||||
Currency
|
|
Settlement Price
($ per Euro)
|
|
Type
|
|
Notional Amount
|
|
Fair Value
|
|
Notional Amount
|
|
Fair Value
|
||||||||
Euro
|
|
1.256
|
|
Sell Euro
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
6,000
|
|
|
$
|
241
|
|
Euro
|
|
1.257
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
15,750
|
|
|
728
|
|
||||
Euro
|
|
1.259
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
16,125
|
|
|
752
|
|
||||
Euro
|
|
1.260
|
|
Sell Euro
|
|
33,000
|
|
|
4,597
|
|
|
33,000
|
|
|
1,468
|
|
||||
Euro
|
|
1.270
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
7,000
|
|
|
377
|
|
||||
Euro
|
|
1.281
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
8,000
|
|
|
503
|
|
||||
Total
|
|
|
|
|
|
$
|
33,000
|
|
|
$
|
4,597
|
|
|
$
|
85,875
|
|
|
$
|
4,069
|
|
Cash Flow Hedge
|
|
Location
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
(In thousands)
|
|
|
|
|
|
|
||||
Euro contracts
|
|
Prepaid and other current assets
|
|
$
|
4,597
|
|
|
$
|
3,352
|
|
Euro contracts
|
|
Other assets
|
|
$
|
—
|
|
|
$
|
717
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
(In thousands)
|
|
|
|
|
|
|
|
|
||||||||
Net gain (loss) recognized in OCI, net of tax
(1)
|
|
$
|
(57
|
)
|
|
$
|
1,974
|
|
|
$
|
4,306
|
|
|
$
|
2,305
|
|
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax
(2)
|
|
$
|
1,495
|
|
|
$
|
(989
|
)
|
|
$
|
3,903
|
|
|
$
|
(3,744
|
)
|
Net gain (loss) recognized in interest and other income, net - cash flow hedges
(3)
|
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
—
|
|
|
$
|
5
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
(In thousands)
|
|
|
|
|
||||
Compensation
|
|
$
|
3,588
|
|
|
$
|
1,332
|
|
Interest
|
|
2,000
|
|
|
6,210
|
|
||
Dividend payable
|
|
24,735
|
|
|
90
|
|
||
Legal
|
|
1,139
|
|
|
296
|
|
||
Other
|
|
1,249
|
|
|
948
|
|
||
Total
|
|
$
|
32,711
|
|
|
$
|
8,876
|
|
|
|
|
|
Principal Balance Outstanding
|
|
Carrying Value
|
||||||||
|
|
|
|
September 30,
|
|
September 30,
|
|
December 31,
|
||||||
Description
|
|
Maturity Date
|
|
2015
|
|
2015
|
|
2014
|
||||||
(In thousands)
|
|
|
|
|
|
|
|
|
||||||
Convertible Notes
|
|
|
|
|
|
|
|
|
||||||
Series 2012 Notes
|
|
February 15, 2015
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,261
|
|
May 2015 Notes
|
|
May 1, 2015
|
|
$
|
—
|
|
|
—
|
|
|
153,235
|
|
||
February 2018 Notes
|
|
February 1, 2018
|
|
$
|
300,000
|
|
|
281,581
|
|
|
276,228
|
|
||
March 2015 Term Loan
|
|
February 15, 2016
|
|
$
|
50,000
|
|
|
49,842
|
|
|
—
|
|
||
Total
|
|
|
|
|
|
|
$
|
331,423
|
|
|
$
|
451,724
|
|
(In thousands)
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Principal amount of the Series 2012 Notes
|
|
$
|
—
|
|
|
$
|
22,337
|
|
Unamortized discount of liability component
|
|
—
|
|
|
(76
|
)
|
||
Total
|
|
$
|
—
|
|
|
$
|
22,261
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
(In thousands)
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Contractual coupon interest
|
|
$
|
—
|
|
|
$
|
347
|
|
|
$
|
80
|
|
|
$
|
1,455
|
|
Amortization of debt issuance costs
|
|
—
|
|
|
64
|
|
|
13
|
|
|
996
|
|
||||
Amortization of debt discount
|
|
—
|
|
|
404
|
|
|
76
|
|
|
1,783
|
|
||||
Total
|
|
$
|
—
|
|
|
$
|
815
|
|
|
$
|
169
|
|
|
$
|
4,234
|
|
(In thousands)
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Principal amount of the May 2015 Notes
|
|
$
|
—
|
|
|
$
|
155,050
|
|
Unamortized discount of liability component
|
|
—
|
|
|
(1,815
|
)
|
||
Total
|
|
$
|
—
|
|
|
$
|
153,235
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
(In thousands)
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Contractual coupon interest
|
|
$
|
—
|
|
|
$
|
1,455
|
|
|
$
|
1,938
|
|
|
$
|
4,366
|
|
Amortization of debt issuance costs
|
|
—
|
|
|
320
|
|
|
435
|
|
|
952
|
|
||||
Amortization of debt discount
|
|
—
|
|
|
1,308
|
|
|
1,815
|
|
|
3,852
|
|
||||
Total
|
|
$
|
—
|
|
|
$
|
3,083
|
|
|
$
|
4,188
|
|
|
$
|
9,170
|
|
•
|
During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds
130%
of the conversion price for the notes on the last day of such preceding fiscal quarter;
|
•
|
During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per
$1,000
principal amount of notes for each trading day of that measurement period was less than
98%
of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
|
•
|
Upon the occurrence of specified corporate events as described further in the indenture; or
|
•
|
At any time on or after August 1, 2017.
|
(In thousands)
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Principal amount of the February 2018 Notes
|
|
$
|
300,000
|
|
|
$
|
300,000
|
|
Unamortized discount of liability component
|
|
(18,419
|
)
|
|
(23,772
|
)
|
||
Total
|
|
$
|
281,581
|
|
|
$
|
276,228
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
(In thousands)
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Contractual coupon interest
|
|
$
|
3,000
|
|
|
$
|
3,000
|
|
|
$
|
9,000
|
|
|
$
|
7,633
|
|
Amortization of debt issuance costs
|
|
510
|
|
|
536
|
|
|
1,599
|
|
|
1,358
|
|
||||
Amortization of debt discount
|
|
1,830
|
|
|
1,688
|
|
|
5,353
|
|
|
4,238
|
|
||||
Total
|
|
$
|
5,340
|
|
|
$
|
5,224
|
|
|
$
|
15,952
|
|
|
$
|
13,229
|
|
|
|
September 30,
|
|
December 31,
|
||||
|
|
2015
|
|
2014
|
||||
(In thousands)
|
|
|
|
|
||||
Accrued lease liability
|
|
$
|
10,700
|
|
|
$
|
10,700
|
|
Long-term incentive accrual
|
|
2,446
|
|
|
578
|
|
||
Uncertain tax positions
|
|
35,035
|
|
|
26,356
|
|
||
Dividend payable
|
|
293
|
|
|
68
|
|
||
Total
|
|
$
|
48,474
|
|
|
$
|
37,702
|
|
|
|
|
|
Stock Options
|
|
Restricted Stock Awards
|
|||||||||||
(In thousands except per share amounts)
|
|
Shares Available for Grant
|
|
Number of Shares Outstanding
|
|
Weighted Average Exercise Price
|
|
Number of Shares Outstanding
|
|
Weighted Average Grant-date Fair Value Per Share
|
|||||||
Balance at December 31, 2014
|
|
4,166
|
|
|
58
|
|
|
$
|
5.41
|
|
|
277
|
|
|
$
|
8.39
|
|
Granted
|
|
(522
|
)
|
|
—
|
|
|
|
|
522
|
|
|
6.40
|
|
|||
Shares released
|
|
—
|
|
|
—
|
|
|
|
|
(46
|
)
|
|
8.58
|
|
|||
Forfeited or canceled
|
|
40
|
|
|
—
|
|
|
|
|
|
(40
|
)
|
|
6.46
|
|
||
Balance at September 30, 2015
|
|
3,684
|
|
|
58
|
|
|
$
|
5.41
|
|
|
713
|
|
|
$
|
7.36
|
|
|
|
Unrealized gains (losses) on available-for-sale securities
|
|
Unrealized gains on cash flow hedges
|
|
Total Accumulated Other Comprehensive Income
|
||||||
(In thousands)
|
|
|
|
|
|
|
||||||
Beginning Balance at December 31, 2014
|
|
$
|
364
|
|
|
$
|
2,585
|
|
|
$
|
2,949
|
|
Activity for the nine months ended September 30, 2015
|
|
39
|
|
|
403
|
|
|
442
|
|
|||
Ending Balance at September 30, 2015
|
|
$
|
403
|
|
|
$
|
2,988
|
|
|
$
|
3,391
|
|
Licensee
|
|
Product Names
|
Genentech
|
|
Avastin
|
|
|
Herceptin
|
|
|
Xolair
|
|
|
Lucentis
|
|
|
Perjeta
®
|
|
|
Kadcyla
®
|
|
|
|
Biogen
|
|
Tysabri
|
|
|
|
Chugai
|
|
Actemra
®
|
|
|
|
Roche
|
|
Gazyva™
|
|
|
|
Takeda
|
|
Entyvio
®
|
|
|
Three Months Ended
|
|
Change from Prior
|
|
Nine Months Ended
|
|
Change from Prior
|
||||||||||||
|
|
September 30,
|
|
|
September 30,
|
|
||||||||||||||
|
|
2015
|
|
2014
|
|
Year %
|
|
2015
|
|
2014
|
|
Year %
|
||||||||
(Dollars in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Royalties from Queen et al. patents
|
|
$
|
119,222
|
|
|
$
|
123,916
|
|
|
(4%)
|
|
$
|
363,916
|
|
|
$
|
355,008
|
|
|
3%
|
Royalty rights - change in fair value
|
|
(4,280
|
)
|
|
27,602
|
|
|
(116%)
|
|
19,298
|
|
|
73,807
|
|
|
(74%)
|
||||
Interest revenue
|
|
9,096
|
|
|
13,076
|
|
|
(30%)
|
|
28,596
|
|
|
34,760
|
|
|
(18%)
|
||||
License and other
|
|
580
|
|
|
—
|
|
|
100%
|
|
580
|
|
|
575
|
|
|
1%
|
||||
Total revenues
|
|
$
|
124,618
|
|
|
$
|
164,594
|
|
|
(24%)
|
|
$
|
412,390
|
|
|
$
|
464,150
|
|
|
(11%)
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||
|
|
|
|
September 30,
|
|
September 30,
|
||||||||
Licensee
|
|
Product Name
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
Genentech
|
|
Avastin
|
|
32
|
%
|
|
24
|
%
|
|
28
|
%
|
|
25
|
%
|
|
|
Herceptin
|
|
32
|
%
|
|
24
|
%
|
|
28
|
%
|
|
25
|
%
|
|
|
Xolair
|
|
10
|
%
|
|
6
|
%
|
|
8
|
%
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
||||
Biogen
|
|
Tysabri
|
|
11
|
%
|
|
10
|
%
|
|
10
|
%
|
|
9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depomed
|
|
Glumetza
|
|
(10
|
)%
|
|
14
|
%
|
|
—
|
%
|
|
13
|
%
|
|
|
Three Months Ended
|
|
Change from Prior
|
|
Nine Months Ended
|
|
Change from Prior
|
||||||||||||
|
|
September 30,
|
|
|
September 30,
|
|
||||||||||||||
|
|
2015
|
|
2014
|
|
Year %
|
|
2015
|
|
2014
|
|
Year %
|
||||||||
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
General and administrative
|
|
$
|
8,450
|
|
|
$
|
5,686
|
|
|
49%
|
|
$
|
23,545
|
|
|
$
|
17,188
|
|
|
37%
|
Percentage of total revenues
|
|
7
|
%
|
|
3
|
%
|
|
|
|
6
|
%
|
|
4
|
%
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
September 30,
|
|
September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net income per share - basic
|
$
|
0.42
|
|
|
$
|
0.64
|
|
|
$
|
1.42
|
|
|
$
|
1.70
|
|
Net income per share - diluted
|
$
|
0.42
|
|
|
$
|
0.61
|
|
|
$
|
1.42
|
|
|
$
|
1.62
|
|
•
|
During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds
130%
of the conversion price for the notes on the last day of such preceding fiscal quarter;
|
•
|
During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per
$1,000
principal amount of notes for each trading day of that measurement period was less than
98%
of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
|
•
|
Upon the occurrence of specified corporate events as described further in the indenture; or
|
•
|
At any time on or after August 1, 2017.
|
Euro Forward Contracts
|
|
September 30, 2015
|
|
December 31, 2014
|
|||||||||||||||||
|
|
|
|
|
|
(In thousands)
|
|
(In thousands)
|
|||||||||||||
Currency
|
|
Settlement Price
|
|
Type
|
|
Notional Amount
|
|
Fair Value
|
|
Notional Amount
|
|
Fair Value
|
|||||||||
|
($ per Euro)
|
|
|
|
|
|
|||||||||||||||
Euro
|
|
1.256
|
|
|
Sell Euro
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
6,000
|
|
|
$
|
241
|
|
Euro
|
|
1.257
|
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
15,750
|
|
|
728
|
|
||||
Euro
|
|
1.259
|
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
16,125
|
|
|
752
|
|
||||
Euro
|
|
1.260
|
|
|
Sell Euro
|
|
33,000
|
|
|
4,597
|
|
|
33,000
|
|
|
1,468
|
|
||||
Euro
|
|
1.270
|
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
7,000
|
|
|
377
|
|
||||
Euro
|
|
1.281
|
|
|
Sell Euro
|
|
—
|
|
|
—
|
|
|
8,000
|
|
|
503
|
|
||||
Total
|
|
|
|
|
|
|
$
|
33,000
|
|
|
$
|
4,597
|
|
|
$
|
85,875
|
|
|
$
|
4,069
|
|
Dated:
|
November 4, 2015
|
|
PDL BIOPHARMA, INC. (REGISTRANT)
|
|
|
|
|
|
|
|
|
/s/ John P. McLaughlin
|
|
|
John P. McLaughlin
|
|
|
President and Chief Executive Officer (Principal Executive Officer)
|
|
/s/ Peter S. Garcia
|
|
|
Peter S. Garcia
|
|
|
Vice President and Chief Financial Officer (Principal Financial Officer)
|
|
/s/ Steffen Pietzke
|
|
|
Steffen Pietzke
|
|
|
Controller and Chief Accounting Officer (Principal Accounting Officer)
|
|
#
|
Filed herewith.
|
*
|
Management contract or compensatory plan or arrangement
|
**
|
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under
|
†
|
Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.
|
Name
|
Title
|
Target Bonus
|
Ratio of 2015 Corporate Goals/2015 Individual Goals
|
John McLaughlin
|
President & CEO
|
100%
|
100%/0%
|
Peter Garcia
|
VP & CFO
|
75%
|
75%/25%
|
Christopher Stone
|
VP, General Counsel & Secretary
|
75%
|
75%/25%
|
Danny Hart
|
Vice President, Business Development
|
75%
|
75%/25%
|
Steffen Pietzke
|
Controller and Chief Accounting Officer
|
45%
|
75%/25%
|
Nathan Kryszak
|
Senior Counsel & Assistant Secretary
|
45%
|
75%/25%
|
1.
|
Eligibility
|
2.
|
Performance Goals
|
3.
|
Incentive
|
4.
|
Adjustments
|
5.
|
Change in Control
|
6.
|
409A
|
7.
|
162(m)
|
8.
|
Miscellaneous
|
Name
|
|
Title
|
|
Target Cash Payment
|
Value of Restricted Stock Award
|
John P. McLaughlin
|
|
President and Chief Executive Officer
|
|
$2,297,190
|
$984,510
|
Peter Garcia
|
|
Vice President, Chief Financial Officer
|
|
$759,229
|
$325,384
|
Christopher L. Stone
|
|
Vice President, General Counsel and Secretary
|
|
$765,310
|
$327,990
|
Danny Hart
|
|
Vice President, Business Development
|
|
$710,500
|
$304,500
|
Steffen Pietzke
|
|
Controller & Chief Accounting Officer
|
|
$233,920
|
$100,254
|
Nathan Kryszak
|
|
Senior Counsel and Assistant Secretary
|
|
$328,020
|
$140,580
|
ARTICLE I
DEFINITIONS |
1
|
Section 1.01
|
Definitions.
1
|
ARTICLE II
PURCHASE OF ASSIGNED INTERESTS |
15
|
Section 2.01
|
Purchase.
15
|
Section 2.02
|
Payments by the Company.
15
|
Section 2.03
|
Closing; Payment of Closing Purchase Price; Closing Deliveries; Payment of Additional Purchase Price.
16
|
Section 2.04
|
Make Whole Payments.
17
|
Section 2.05
|
No Assumed Obligations.
18
|
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF COMPANY |
19
|
Section 3.01
|
Organization.
19
|
Section 3.02
|
Authorization.
19
|
Section 3.03
|
Governmental Authorization.
19
|
Section 3.04
|
Ownership.
19
|
Section 3.05
|
Financial Statements.
20
|
Section 3.06
|
No Undisclosed Liabilities.
20
|
Section 3.07
|
Solvency.
21
|
Section 3.08
|
Litigation.
21
|
Section 3.09
|
Compliance with Laws.
21
|
Section 3.10
|
Conflicts.
21
|
Section 3.11
|
Subordination.
22
|
Section 3.12
|
Intellectual Property.
22
|
Section 3.13
|
Regulatory Approval.
24
|
Section 3.14
|
Material Contracts.
25
|
Section 3.15
|
Place of Business.
25
|
Section 3.16
|
Broker’s Fees.
25
|
Section 3.17
|
Other Information.
25
|
Section 3.18
|
Taxes.
25
|
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER |
26
|
Section 4.01
|
Organization.
26
|
Section 4.02
|
Authorization.
26
|
Section 4.03
|
Broker’s Fees.
26
|
Section 4.04
|
Conflicts.
26
|
ARTICLE V
COVENANTS |
27
|
Section 5.01
|
Consents and Waivers.
27
|
Section 5.02
|
Access; Information.
27
|
Section 5.03
|
Material Contracts.
28
|
Section 5.04
|
Confidentiality; Public Announcement.
29
|
Section 5.05
|
Security Agreement.
29
|
Section 5.06
|
Efforts; Further Assurance.
30
|
Section 5.07
|
Put Option; Call Option.
30
|
Section 5.08
|
[Remittance to Deposit Account].
31
|
Section 5.09
|
Intellectual Property.
35
|
Section 5.10
|
Protective Covenants.
36
|
Section 5.11
|
Insurance.
37
|
Section 5.12
|
Notice.
38
|
Section 5.13
|
Use of Proceeds.
38
|
ARTICLE VI
TERMINATION |
40
|
Section 6.01
|
Termination Date.
40
|
Section 6.02
|
Effect of Termination.
40
|
ARTICLE VII
MISCELLANEOUS |
40
|
Section 7.01
|
Survival.
40
|
Section 7.02
|
Specific Performance; Limitations on Damages.
41
|
Section 7.03
|
Notices.
41
|
Section 7.04
|
Successors and Assigns.
42
|
Section 7.05
|
Indemnification.
43
|
Section 7.06
|
No Implied Representations and Warranties.
44
|
Section 7.07
|
Independent Nature of Relationship.
44
|
Section 7.08
|
Tax Treatment.
45
|
Section 7.09
|
Entire Agreement.
45
|
Section 7.10
|
Amendments; No Waivers.
45
|
Section 7.11
|
Interpretation.
46
|
Section 7.12
|
Headings and Captions.
46
|
Section 7.13
|
Counterparts; Effectiveness.
46
|
Section 7.14
|
Severability.
46
|
Section 7.15
|
Expenses.
46
|
Section 7.16
|
Governing Law; Jurisdiction.
46
|
Section 7.17
|
Waiver of Jury Trial.
47
|
Exhibit A
|
|
–
|
|
Form of Security Agreement
|
Exhibit B
|
|
–
|
|
Form of Assignment of Interests
|
Exhibit C
|
|
|
|
Form of Legal Opinion (Mintz Levin)
|
Period
|
Multiple
|
On or prior to the first anniversary of the Closing Date
|
1.15x
|
After the first anniversary of the Closing Date through and including the second anniversary of the Closing Date
|
1.20x
|
After the second anniversary of the Closing Date and thereafter
|
1.30x
|
|
|
|
|
|
|
|
COMPANY:
|
|
|
|
ARIAD PHARMACEUTICALS, INC.
|
||
|
|
|
|
|||
|
|
|
|
|
By:
/s/ Harvey J. Berger, M.D.
|
|
|
|
|
|
|
Name: Harvey J. Berger, M.D.
Title: Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
||||
PURCHASER:
|
|
|
|
PDL BIOPHARMA, INC.
|
||
|
|
|
|
|||
|
|
|
|
|
By:
/s/ John P. McLaughlin
|
|
|
|
|
|
|
Name: John P. McLaughlin
Title: Chief Executive Officer
|
|
|
|
|
|
|
|
|
(i)
|
PATENTS AND PENDING APPLICATIONS
|
(ii)
|
TRADEMARKS
|
(iii)
|
COPYRIGHTS
|
(iv)
|
DOMAIN NAMES AND WEBSITES
|
|
|
|
ASSIGNOR
:
|
||
|
||
ARIAD PHARMACEUTICALS, INC.
|
||
|
|
|
By:
|
|
|
Name:
|
||
Title:
|
||
|
||
ASSIGNEE
:
|
||
|
||
PDL BIOPHARMA, INC.
|
||
|
|
|
By:
|
|
|
Name:
|
|
|
Title:
|
|
|
•
|
The Company is a corporation validly existing and in corporate good standing under the laws of the State of Delaware.
|
•
|
The Company has the corporate power and authority to enter into and perform its obligations under the Transaction Documents to which it is a party, has taken all necessary corporate action to authorize the execution, delivery and performance of such Transaction Documents and has duly executed and delivered such Transaction Documents.
|
•
|
Each Transaction Document to which the Company is a party is the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.
|
•
|
The execution and delivery by the Company of the Transaction Documents to which it is a party do not, and the compliance by the Company with its obligations thereunder will not, (i) result in a violation of the Certificate of Incorporation and the Bylaws of the Company, (ii) result in a breach or default under any material agreement of the Company, (iii) result in a violation of any order binding upon the Company or (iv) to our knowledge, result in or require the creation or imposition of any lien or encumbrance upon any assets of the Company under any material agreement of the Company (for the avoidance of doubt, any liens and security interests created pursuant to the Transaction Documents are excluded from this clause), and any material contracts or binding orders may be identified in a backup officer’s certificate from the Company.
|
•
|
The execution and delivery by the Company of the Transaction Documents to which it is a party do not, and the compliance by each of the Company with its obligations thereunder will not, require any approval from or filing with any governmental authority of the United States, the State of New York, or the State of Delaware, other than the filings and records contemplated by the Transaction Documents to perfect security interests.
|
•
|
The execution and delivery by each of the Company of the Transaction Documents to which it is a party do not, and the compliance by the Company with its obligations thereunder will not, result in any violation of any federal law of the United States, the law of the State of New York or any regulation thereunder, or the law of the State of Delaware or any regulation thereunder, which, in our experience are applicable to, or relevant in connection with, transactions of the type provided for in the Transaction Documents.
|
•
|
Neither the Company nor any Subsidiary of the Company is an “investment company” within the meaning of, and subject to regulation under, the Investment Company Act of 1940, as amended.
|
•
|
The Security Agreement is effective to create in favor of the Purchaser, as security for the Secured Obligations, as defined in the Security Agreement, a security interest (the “Article 9 Security Interest”) in the Collateral as described in the Security Agreement to the extent that a security interest may be created therein under Article 9 of the New York UCC (the “Article 9 Collateral”).
|
•
|
Upon the proper filing of the UCC Financing Statement with the Delaware Secretary of State, the Article 9 Security Interest will be perfected to the extent that a security interest can be perfected by the filing of financing statements pursuant to Article 9 of the Delaware UCC.
|
•
|
The Article 9 Security Interest in the Joint Concentration Account (to the extent constituting Collateral as defined in the Security Agreement) and the Article 9 Security Interest in the Purchaser Concentration Account will be perfected by control upon the execution and delivery of the Security Agreement and the Deposit Agreement and will rank prior to any other security interest in the Joint Concentration Account (to the extent constituting Collateral as defined in the Security Agreement) and the Purchaser Concentration Account that is not perfected by control under Article 9 of the New York UCC.
|
2015
|
$
|
—
|
|
2016
|
$
|
—
|
|
2017
|
$
|
—
|
|
2018
|
$
|
—
|
|
2019
|
$
|
* * *
|
|
2020
|
$
|
* * *
|
|
2021
|
$
|
* * *
|
|
2022
|
$
|
* * *
|
|
2023
|
$
|
* * *
|
|
2024
|
$
|
* * *
|
|
2025
|
$
|
* * *
|
|
2026
|
$
|
* * *
|
|
2027
|
$
|
* * *
|
|
2028
|
$
|
* * *
|
|
2029
|
$
|
* * *
|
|
2030
|
$
|
* * *
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, 2015
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
|||||||||||||
Earnings:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Income before income taxes
|
|
$
|
150,370
|
|
|
$
|
307,428
|
|
|
$
|
327,133
|
|
|
$
|
401,876
|
|
|
$
|
501,272
|
|
|
$
|
367,429
|
|
Add: fixed charges
|
|
43,578
|
|
|
36,153
|
|
|
29,097
|
|
|
24,931
|
|
|
39,274
|
|
|
21,758
|
|
||||||
Earnings
|
|
$
|
193,948
|
|
|
$
|
343,581
|
|
|
$
|
356,230
|
|
|
$
|
426,807
|
|
|
$
|
540,546
|
|
|
$
|
389,187
|
|
Fixed Charges:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Interest expense
1
|
|
$
|
43,529
|
|
|
$
|
36,102
|
|
|
$
|
29,036
|
|
|
$
|
24,871
|
|
|
$
|
39,211
|
|
|
$
|
21,710
|
|
Estimated interest portion of rent expense
2
|
|
49
|
|
|
51
|
|
|
61
|
|
|
60
|
|
|
63
|
|
|
48
|
|
||||||
Fixed charges
|
|
43,578
|
|
|
$
|
36,153
|
|
|
$
|
29,097
|
|
|
$
|
24,931
|
|
|
$
|
39,274
|
|
|
$
|
21,758
|
|
|
Ratio of earnings to fixed charges
|
|
4.45
|
|
|
9.50
|
|
|
12.24
|
|
|
17.12
|
|
|
13.76
|
|
|
17.89
|
|
Date:
|
November 4, 2015
|
|
|
|
|
/s/ John P. McLaughlin
|
|
|
John P. McLaughlin
President and Chief Executive Officer
(Principal Executive Officer)
|
|
Date:
|
November 4, 2015
|
|
|
|
|
/s/ Peter S. Garcia
|
|
|
Peter S. Garcia
Vice President and Chief Financial Officer
(Principal Financial Officer)
|
|
|
By:
|
|
|
|
/s/ JOHN P. MCLAUGHLIN
|
|
|
John P. McLaughlin
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
By:
|
|
|
|
/s/ PETER S. GARCIA
|
|
|
Peter S. Garcia
|
|
|
Vice President and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
(1)
|
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
|